These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34920812)

  • 1. Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy.
    Bohineust A; Tourret M; Derivry L; Caillat-Zucman S
    Bull Cancer; 2021 Oct; 108(10S):S92-S95. PubMed ID: 34920812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal-associated invariant T cells for cancer immunotherapy.
    Li YR; Zhou K; Wilson M; Kramer A; Zhu Y; Dawson N; Yang L
    Mol Ther; 2023 Mar; 31(3):631-646. PubMed ID: 36463401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy.
    Dogan M; Karhan E; Kozhaya L; Placek L; Chen X; Yigit M; Unutmaz D
    J Immunol; 2022 Oct; 209(8):1523-1531. PubMed ID: 36165183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
    Kagoya Y; Guo T; Yeung B; Saso K; Anczurowski M; Wang CH; Murata K; Sugata K; Saijo H; Matsunaga Y; Ohashi Y; Butler MO; Hirano N
    Cancer Immunol Res; 2020 Jul; 8(7):926-936. PubMed ID: 32321775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Human Mucosal-associated Invariant T (MAIT) Cells.
    Souter MNT; Loh L; Li S; Meehan BS; Gherardin NA; Godfrey DI; Rossjohn J; Fairlie DP; Kedzierska K; Pellicci DG; Chen Z; Kjer-Nielsen L; Corbett AJ; McCluskey J; Eckle SBG
    Curr Protoc Immunol; 2019 Dec; 127(1):e90. PubMed ID: 31763790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions.
    Healy K; Pavesi A; Parrot T; Sobkowiak MJ; Reinsbach SE; Davanian H; Tan AT; Aleman S; Sandberg JK; Bertoletti A; Sällberg Chen M
    JHEP Rep; 2021 Aug; 3(4):100318. PubMed ID: 34377970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off the shelf T cell therapies for hematologic malignancies.
    McCreedy BJ; Senyukov VV; Nguyen KT
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
    Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
    Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
    Andrea AE; Chiron A; Sarrabayrouse G; Bessoles S; Hacein-Bey-Abina S
    Front Immunol; 2024; 15():1459818. PubMed ID: 39430751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
    Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
    Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
    Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
    Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B
    Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Cannabidiol on the Functions of Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
    Chantarat N; Pe KCS; Suppipat K; Vimolmangkang S; Tawinwung S
    Cannabis Cannabinoid Res; 2024 Jun; 9(3):819-829. PubMed ID: 37878339
    [No Abstract]   [Full Text] [Related]  

  • 18. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal CAR 2.0 to overcome current limitations in CAR therapy.
    Schlegel LS; Werbrouck C; Boettcher M; Schlegel P
    Front Immunol; 2024; 15():1383894. PubMed ID: 38962014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
    Hill JA; Seo SK
    Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.